Format
Sort by

Send to

Choose Destination

Search results

Items: 3

1.

ADCC employing an NK cell line (haNK) expressing the high affinity CD16 allele with avelumab, an anti-PD-L1 antibody.

Jochems C, Hodge JW, Fantini M, Tsang KY, Vandeveer AJ, Gulley JL, Schlom J.

Int J Cancer. 2017 Aug 1;141(3):583-593. doi: 10.1002/ijc.30767. Epub 2017 May 19.

2.

Enhanced antitumor effects by combining an IL-12/anti-DNA fusion protein with avelumab, an anti-PD-L1 antibody.

Fallon JK, Vandeveer AJ, Schlom J, Greiner JW.

Oncotarget. 2017 Mar 28;8(13):20558-20571. doi: 10.18632/oncotarget.16137.

3.

Systemic Immunotherapy of Non-Muscle Invasive Mouse Bladder Cancer with Avelumab, an Anti-PD-L1 Immune Checkpoint Inhibitor.

Vandeveer AJ, Fallon JK, Tighe R, Sabzevari H, Schlom J, Greiner JW.

Cancer Immunol Res. 2016 May;4(5):452-62. doi: 10.1158/2326-6066.CIR-15-0176. Epub 2016 Feb 26.

Supplemental Content

Loading ...
Support Center